Orelabrutinib tablets | China Drugs List
Public reference information, not medical advice, a prescription or an offer to supply a medicine. Confirm current approval, availability and suitability with licensed professionals.
- Medicine type
- Chemical medicine
- Therapeutic area
- Oncology
- Indications recorded in the public source
- (1) Adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). (2) Adults with mantle cell lymphoma (MCL) after at least one previous treatment. (3) Adults with marginal zone lymphoma (MZL) after at least one previous treatment.
- Indication source and scope
- Source date(s): 2025-05-19. Manufacturer prescribing information for Mainland China.
- Prescribing-information limitations
- Complete official prescribing information obtained. Mainland China label.
- China availability status
- Historical Chinese approval verified; current continuous market availability has not been checked for every product.
- Overseas status
- Market-by-market verification pending.
- Insurance classification
- Included in national insurance (Category B)
- Insurance edition
- 2025 edition; effective 1 January 2026
- Insurance restrictions
- Restricted to: (1) Adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). (2) Adults with mantle cell lymphoma (MCL) after at least one previous treatment. (3) Adults with marginal zone lymphoma (MZL) after at least one previous treatment.
- Insurance period
- 2026-01-01 to 2027-12-31
- Insurance verification notes
- Matched by exact or normalized ingredient/formulation name. Reimbursement still depends on the dosage form and listed payment restrictions.
Sources
- https://www.cnpharm.com/upload/resources/file/2021/06/21/92867.docx
- https://www.nhsa.gov.cn/module/download/downfile.jsp?classid=0&filename=a32f9f2f3fc046afaf08471f87456ce3.pdf
- https://www.innocarepharma.com/uploads/2026-02-26/file-1772091157282-544878128.pdf
Open the interactive record, public price references and discussions